The U.S. Federal Circuit Court has recently issued several rulings impacting patent law and intellectual property litigation. It reversed an injunction that had barred clinical trials in the case of Jazz Pharmaceuticals versus Avadel. The court also affirmed the Patent Trial and Appeal Board's (PTAB) findings of unpatentability in inter partes reviews concerning gene therapy patents related to Hemgenix®. Additionally, the Federal Circuit clarified the limits on relying solely on U.S. Patent and Trademark Office (USPTO) findings in patent eligibility disputes under Section 101, highlighting divergence between USPTO and district court analyses. The court has also expanded the International Trade Commission's (ITC) role as a venue for life sciences patent disputes. Meanwhile, the U.S. Patent and Trademark Office (USPTO) acting director reinstated patent claims for Longhorn Vaccines & Diagnostics LLC that had previously been invalidated by her predecessor as a sanction for misconduct. These developments reflect ongoing adjustments in patent litigation and administrative patent proceedings, particularly in the life sciences sector.